Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $439 from $460 and keeps an Equal Weight rating on the shares. Pipeline setbacks, including Journavx not advancing into a Phase 3 LSR trial and pain signal inhibitor VX-993 being found to be not differentiated in acute, likely will be a focus and drive weakness in the stock despite Vertex having posted a Q2 beat, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strong Financials Overshadowed by Challenges in Pain Program Leading to Hold Rating
- Vertex Pharmaceuticals: Strong Financial Performance and Promising Pipeline Justify Buy Rating
- Vertex Stock (VRTX) Crashes after Pain-Drug Trial Failure Despite Strong Q2
- Vertex Pharmaceuticals: Strong Buy Rating Amid Robust Financials and Market Potential Despite Setbacks
- Vertex Pharmaceuticals Reports Strong Q2 2025 Growth